Xtalks Life Science Podcast

Xtalks
  • 5.0 (1)
  • LIFE SCIENCES
  • UPDATED WEEKLY
Xtalks Life Science Podcast

This Life Science focused podcast brings together Xtalks editorial staff to share insights into the latest B2B industry news. Xtalks connects professionals in the life science, medical device, and food industries with useful content like webinars, job opening, articles and virtual meetings.

  1. 6 DAYS AGO · VIDEO

    Advancing PTSD Treatment with Digital Brain Biomarkers ft. Oded Kraft, Co-Founder, CEO and President of GrayMatters Health

    In this episode, Vera speaks with Oded Kraft, Co-Founder, CEO and President of GrayMatters Health, a company transforming mental health care through evidence-based digital brain biomarker technology. Oded shares insights into GrayMatters Health’s mission to improve patient outcomes for mental health disorders like PTSD by leveraging their proprietary EEG-fMRI-Pattern (EFP) biomarker. He discusses how this novel technology integrates functional MRI and EEG data to address critical gaps in mental health treatment, offering a personalized approach for patients. With over 20 years of leadership experience at companies like GE Healthcare, Medingo-Roche and Kornit Digital, Oded also reflects on his journey in healthcare innovation, the challenges of scaling cutting-edge technologies and his vision for the future of mental health treatment. Tune in to learn how GrayMatters Health is shaping the future of PTSD treatment and making mental health care more effective worldwide. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/Follow Us on Social Media Twitter: https://twitter.com/XtalksInstagram: https://www.instagram.com/xtalks/Facebook: https://www.facebook.com/Xtalks.Webinars/LinkedIn: https://www.linkedin.com/company/xtalks-webconferencesYouTube: https://www.youtube.com/c/XtalksWebinars/featured

    25 min

  2. FEB 5 · VIDEO

    Innovating Immune-Modulating Therapies in Autoimmune Disorders ft. Dr. Mario Marcondes, VP Head of Clinical Development, Nektar Therapeutics

    In this episode, Ayesha spoke with Mario Marcondes, MD, PhD, VP Head of Clinical Development at Nektar Therapeutics, a company focused on the discovery and development of novel therapies for autoimmune disorders and cancer. Dr. Marcondes is a licensed and trained physician, specializing in oncology and immune oncology. He has more than 15 years of research and teaching experience in Bone Marrow Transplant (BMT)/Cellular Therapies and more than 10 years of industry experience. He was the Program Lead for early-stage assets at Nektar and manages clinical trial programs from Phase I through to Phase III. Dr. Marcondes is a member of multiple professional clinical and translational research organizations, including the American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH), American Association for Cancer Research (AACR) and Center for International Blood & Marrow Transplant Research (CIBMTR). Listen to the episode to hear about the current research landscape in autoimmune disorders, including the work Dr. Marcondes is leading at Nektar Therapeutics. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/Follow Us on Social Media Twitter: https://twitter.com/XtalksInstagram: https://www.instagram.com/xtalks/Facebook: https://www.facebook.com/Xtalks.Webinars/LinkedIn: https://www.linkedin.com/company/xtalks-webconferencesYouTube: https://www.youtube.com/c/XtalksWebinars/featured

    40 min

  3. JAN 29 · VIDEO

    Advancing Digital Approaches in Alzheimer’s Research and Care ft. Sarah Averill Lott, Research Lead, Digital Medicine Society (DiMe) & Diane Stephenson, Executive Director, Critical Path for Parkinson

    In this episode, Ayesha spoke with Sarah Averill Lott, MPH, CPH, Research Lead at Digital Medicine Society (DiMe) and Diane Stephenson, PhD, Executive Director at the Critical Path for Parkinson (CPP) at the Critical Path Institute. DiMe is a global non-profit and a professional home for digital medicine that aims to drive the broad adoption of digital approaches to advance medicine and public health. DiMe convened a working group to identify barriers to greater utilization of digital measures in Alzheimer's research and subsequently developed resources to help researchers and clinicians more quickly adopt digital measures in this area. Sarah Averill Lott is a program lead at DiMe where she supports programs and resources that promote the safe, effective and equitable use of digital health technologies to advance clinical research and improve outcomes for patients. She has degrees in neuroscience and public health. Diane Stephenson is a neuroscientist by training with 35 years combined experience in academic neuroscience and drug discovery. Dr Stephenson joined Critical Path Institute in 2011 and presently leads the Neurology programs centered around Critical Path for Parkinson’s (CPP) and Critical Path for Alzheimer’s Disease (CPAD), with the goal of accelerating drug development tools for neurodegenerative diseases. Dr. Stephenson received her PhD in Medical Neurobiology from Indiana University. Tune into the episode to hear about the adoption of digital measures in Alzheimer’s research and care, including the collaboration between DiMe and the Critical Path Institute. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/Follow Us on Social Media Twitter: https://twitter.com/XtalksInstagram: https://www.instagram.com/xtalks/Facebook: https://www.facebook.com/Xtalks.Webinars/LinkedIn: https://www.linkedin.com/company/xtalks-webconferencesYouTube: https://www.youtube.com/c/XtalksWebinars/featured

    49 min

  4. JAN 22 · VIDEO

    Transformative Neuropsychiatric Therapies ft. Dr. Amit Etkin, Founder, President and CEO of Alto Neuroscience

    In this episode, Ayesha spoke with Amit Etkin, Founder, President and CEO of Alto Neuroscience, a company developing precision treatments for neuropsychiatric conditions. Alto Neuroscience is focused on designing candidates that target core brain processes in patient populations not adequately treated by currently available medications. Alto is currently pursuing candidates in major depressive disorder (MDD), bipolar depression and schizophrenia. Mental health disorders are a leading cause of disability globally. In the US alone, 1 in 5 people are living with a mental health disorder, with an estimated $280 billion spent on mental health services in the country in 2020. Despite significant need, the current standard of care consists of treatments that are ineffective for many patients. Dr. Amit Etkin founded Alto in 2019 and is the president, CEO and serves as chair of the company’s board of directors. Prior to founding Alto, Dr. Etkin was a tenured professor of psychiatry and behavioral sciences at Stanford University, where he held multiple leading roles. His research contributions during his tenure at Stanford led to Dr. Etkin being awarded the National Institutes of Health (NIH) Director’s Pioneer Award, the most competitive and prestigious NIH grant, and the first in history to be awarded in clinical psychiatry. He also received an Entrepreneur of the Year (EY) award. Tune into the episode to hear from Dr. Etkin about innovations in treatments for neuropsychiatric disorders at Alto Neuroscience. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/Follow Us on Social Media Twitter: https://twitter.com/XtalksInstagram: https://www.instagram.com/xtalks/Facebook: https://www.facebook.com/Xtalks.Webinars/LinkedIn: https://www.linkedin.com/company/xtalks-webconferencesYouTube: https://www.youtube.com/c/XtalksWebinars/featured

    31 min

  5. JAN 15 · VIDEO

    Pioneering Cancer Treatment with Alpha Radiation Technology ft. Alpha Tau Medical CMO Dr. Robert Den

    In this episode, Vera spoke with Dr. Robert Den, Chief Medical Officer (CMO) of Alpha Tau Medical, a company developing cancer treatment with its highly potent alpha radiation technology. Dr. Den shared his journey to becoming CMO at Alpha Tau Medical and discussed the company’s mission to bring innovative cancer therapies to patients worldwide. Learn how Alpha Tau’s technology differs from traditional radiation therapies, the types of cancers it has shown promise in treating and the impact this novel, investigational approach could have on patient care. With his expertise in radiation oncology and his role as an Associate Professor and Clinical Practitioner at Jefferson University, Dr. Den also provided insights into the challenges in the field and shared his vision for the future of cancer treatment. Don’t miss this episode to hear about Alpha Tau Medical’s recent advancements and Dr. Den’s advice for aspiring leaders in the biotech and medical industries. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/Follow Us on Social Media Twitter: https://twitter.com/XtalksInstagram: https://www.instagram.com/xtalks/Facebook: https://www.facebook.com/Xtalks.Webinars/LinkedIn: https://www.linkedin.com/company/xtalks-webconferencesYouTube: https://www.youtube.com/c/XtalksWebinars/featured

    22 min

  6. JAN 8 · VIDEO

    Innovations in Immunomodulators for Diseases of the Immune System ft. Dr. Judy Chou, CEO, AltruBio

    In this episode, Ayesha spoke with Judy Chou, PhD, CEO, President and Board member of AltruBio, a company developing first-in-class immunomodulators to target diseases of the immune system. AltruBio’s pipeline includes compounds being investigated for indications such as ulcerative colitis, psoriatic arthritis and acute graft vs. host disease. Prior to joining AltruBio, Dr. Chou headed the global Biotech organization at Bayer Pharmaceuticals overseeing the development, manufacturing and distribution of Bayer’s biotechnology pipeline, product portfolio & more than 2,000 employees. Before Bayer, Dr. Chou held various leadership roles at biopharmaceutical companies such as Pfizer/Medivation, Tanvex Biopharma, Genentech, Pfizer (Wyeth) and AbbVie (Abbott). Dr. Chou has extensive experience in biologics development with multiple filings of BLAs, NDAs and INDs of novel products. She is well recognized by the biomedical industry for her leadership and received the Most Influential Women in Business Award in 2018 by San Francisco Business Times. Currently, Dr. Chou also serves as the Board of Directors of Akero Therapeutics, the California Institute of Regenerative Medicines (CIRM); and the Advisory Board members of UC Berkeley Engineering School and Silicon Valley Women in Engineering. Before joining the industry, Dr. Chou was a research faculty member at Harvard University Medical School. Dr. Chou obtained her PhD from Yale University and completed her post-doctoral training at Max-Planck Institute in Germany. Tune into the episode to learn about AltruBio’s innovative solutions targeting diseases of inflammation. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/Follow Us on Social Media Twitter: https://twitter.com/XtalksInstagram: https://www.instagram.com/xtalks/Facebook: https://www.facebook.com/Xtalks.Webinars/LinkedIn: https://www.linkedin.com/company/xtalks-webconferencesYouTube: https://www.youtube.com/c/XtalksWebinars/featured

    35 min

  7. 12/18/2024 · VIDEO

    Innovating Cell-Based Solutions for Type 1 Diabetes ft. Jonathan Rigby, CEO, Sernova

    In this episode, Ayesha spoke with Jonathan Rigby, MBA, CEO of Sernova, a Canadian biotech company developing innovative cell therapy-based approaches for the management of type 1 diabetes. The company’s lead innovation is an implantable bio-hybrid organ pouch, which is currently in an ongoing Phase I/II clinical trial. An estimated 537 million people are currently living with diabetes globally and this number is projected to reach 643 million by 2030, making it a pressing health issue in need of new, effective solutions. Jonathan has held leaderships positions at several biopharmaceutical companies over his career. Prior to heading Sernova as its CEO, Jonathan served as President and CEO of Revolo Biotherapeutics where he took the company through multiple financings and two Phase II clinical trials. He also served as Chairman and Chief Business Officer of BIOS Acquisition Corporation, with an oversold IPO. He also currently serves on the Board of Directors of cancer therapy company Oncolytics Biotech Inc. and IM Therapeutics, which is developing therapies for type 1 diabetes. Tune into the episode to learn about Sernovo’s innovative cell-based approaches for the development of type 1 diabetes treatments. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/Follow Us on Social Media Twitter: https://twitter.com/XtalksInstagram: https://www.instagram.com/xtalks/Facebook: https://www.facebook.com/Xtalks.Webinars/LinkedIn: https://www.linkedin.com/company/xtalks-webconferencesYouTube: https://www.youtube.com/c/XtalksWebinars/featured

    48 min

  8. 12/12/2024 · VIDEO

    Immune-Based Intratumoral Cancer Therapies ft. Intensity Therapeutics founder and CEO Lewis Bender

    In this episode, Ayesha had a conversation with Lewis Bender, MBA, Founder, Chairman and CEO of Intensity Therapeutics, a biotech company developing first-in-class immune-based intratumorally injected cancer therapies. Intensity’s lead product candidate, INT230-6, is currently in human clinical studies for the treatment of refractory solid tumors, including metastatic soft tissue sarcoma and breast cancer. Lewis Bender has almost three decades (28 years) of biopharmaceutical leadership experience and has helped take innovative new products from discovery through to product approval. Lewis has held various leadership roles at biopharmaceutical companies including Interleukin Genetics and Emisphere Technologies. During his career, Lewis has partnered with several major pharmaceutical and biotech companies, with success raising capital from institutional investors through multiple types of transactions. Tune into the episode, to hear more about the work Lewis is heading at Intensity Therapeutics to bring innovative, targeted intratumoral cancer therapies to patients. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/Follow Us on Social Media Twitter: https://twitter.com/XtalksInstagram: https://www.instagram.com/xtalks/Facebook: https://www.facebook.com/Xtalks.Webinars/LinkedIn: https://www.linkedin.com/company/xtalks-webconferencesYouTube: https://www.youtube.com/c/XtalksWebinars/featured

    42 min
See All (195)

About

This Life Science focused podcast brings together Xtalks editorial staff to share insights into the latest B2B industry news. Xtalks connects professionals in the life science, medical device, and food industries with useful content like webinars, job opening, articles and virtual meetings.

Information

  • Creator
    Xtalks
  • Years Active
    2021 - 2025
  • Episodes
    195
  • Rating
    Clean
  • Copyright
    © 2024 Honeycomb Worldwide Inc.
  • Show Website
    Xtalks Life Science Podcast

You Might Also Like

To listen to explicit episodes, sign in.

Stay up to date with this show

Sign in or sign up to follow shows, save episodes, and get the latest updates.
Select a country or region

Africa, Middle East, and India

Asia Pacific

Europe

Latin America and the Caribbean

The United States and Canada